Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
|---|---|---|---|---|---|
| CC5-M52D9 | Mouse | Mouse CCR5 Protein, Flag,His Tag (Detergent) |  |
|
|
| CC5-H52P5 | Human | Fluorescent Human CCR5 Full Length Protein (VLP) | |||
| CHEK-ATP043 | Human | HEK293/Human CCR5 Stable Cell Line | |||
| CC5-H52P3 | Human | Human CCR5 Full Length Protein (VLP) | |||
| CC5-H52D1 | Human | Human CCR5 Protein, Flag,His Tag (Detergent) |  |
|
FACS assay shows that Anti-CCR5 antibody can bind to HEK293/Human CCR5 Stable Cell Line. HEK293/Human CCR5 Stable Cell Line was red line, Negative control HEK293 cells was grey line (QC tested).
Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) captured on CM5 chip via anti-His antibody can bind Anti-CCR5 antibody (Human IgG1) with an affinity constant of 0.0737 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
Purified NA/LE Mouse Anti-Human CD195 (Clone: 2D7) (Mouse IgG2a) captured on CM5 chip via anti-mouse antibodies surface can bind Human CCR5, Flag,His Tag (Cat. No. CC5-H52D1) with an affinity constant of 7.51 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | United States | HIV Infections | Viiv Healthcare Co | 2007-08-06 | HIV Infections; Acquired Immunodeficiency Syndrome; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hypertriglyceridemia; Arthritis, Rheumatoid; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Stroke; AIDS Dementia Complex; Cardiovascular Diseases; Inflammation; HIV Seropositivity; Sarcoma, Kaposi | Details |
| Maraviroc | MVC; UK-427857 | Approved | Viiv Healthcare | Celsentri, Selzentry | United States | HIV Infections | Viiv Healthcare Co | 2007-08-06 | HIV Infections; Acquired Immunodeficiency Syndrome; Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Hypertriglyceridemia; Arthritis, Rheumatoid; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Kidney Diseases; Stroke; AIDS Dementia Complex; Cardiovascular Diseases; Inflammation; HIV Seropositivity; Sarcoma, Kaposi | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Leronlimab | PRO-140; PA-14; HuPRO-140 | Phase 3 Clinical | Cytodyn Inc | HIV Infections; Solid tumours; Metabolic Dysfunction-Associated Steatotic Liver Disease; Triple Negative Breast Neoplasms; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Colorectal Neoplasms; HIV Seropositivity | Details |
| Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Tobira Therapeutics Inc, Takeda Pharmaceutical Co Ltd | Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); AIDS Dementia Complex; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders | Details |
| SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | Details |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | HIV Infections; Acquired Immunodeficiency Syndrome; Colorectal Neoplasms | Details |
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Pancreatic Neoplasms; Colorectal Neoplasms; Hyperplasia; Diabetic Nephropathies; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| AGT 103-T | AGT 103-T | Phase 1 Clinical | American Gene Technologies International Inc | HIV Infections | Details |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | HIV Infections | Details | |
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections; HIV Seropositivity | Details |
| LF-0376 | LF-0376 | Phase 1 Clinical | Wuxi Hillhouse biomedicine Technology Co Ltd | Solid tumours; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colorectal Neoplasms; Lymphoma | Details |
| OB-002 | OB-002; OB-002M; OB-002O; OB-002H; OB-002C; 5P12-RANTES; 5P12-RANTES-E66S | Phase 1 Clinical | Mintaka Medical Research Foundation | HIV Infections; Stomach Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | Details |
| Leronlimab | PRO-140; PA-14; HuPRO-140 | Phase 3 Clinical | Cytodyn Inc | HIV Infections; Solid tumours; Metabolic Dysfunction-Associated Steatotic Liver Disease; Triple Negative Breast Neoplasms; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Colorectal Neoplasms; HIV Seropositivity | Details |
| Cenicriviroc mesylate | CCR5/CCR2 antagonist; TBR-652; CVC; TAK-652 | Phase 3 Clinical | Tobira Therapeutics Inc, Takeda Pharmaceutical Co Ltd | Prediabetic State; HIV Infections; Acquired Immunodeficiency Syndrome; Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease; Liver Cirrhosis; Coronavirus Disease 2019 (COVID-19); AIDS Dementia Complex; Cholangitis, Sclerosing; Hepatic Insufficiency; Obesity; Cognition Disorders | Details |
| SB-728-T | SB-728mR-T; SB-728-T | Phase 2 Clinical | Sangamo Biosciences | HIV Infections | Details |
| Vicriviroc | SCH-D; MK-4176; SCH-417; Sch-417690 | Phase 2 Clinical | Merck & Co Inc | HIV Infections; Acquired Immunodeficiency Syndrome; Colorectal Neoplasms | Details |
| BMS-813160 | BMS-813160 | Phase 2 Clinical | Bristol-Myers Squibb Company | Pancreatic Neoplasms; Colorectal Neoplasms; Hyperplasia; Diabetic Nephropathies; Carcinoma, Pancreatic Ductal; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
| Cenicriviroc mesylate/Tropifexor | LJC-242 | Phase 2 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| AGT 103-T | AGT 103-T | Phase 1 Clinical | American Gene Technologies International Inc | HIV Infections | Details |
| Thioraviroc | Phase 1 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | HIV Infections | Details | |
| BMS-687681 | BMS-687681 | Phase 1 Clinical | Bristol-Myers Squibb Company | Neoplasms | Details |
| SB-728-HSC | SB-728-HSC; SB-728-HSPC; SB-728mR-HSPC | Phase 1 Clinical | Sangamo Biosciences | HIV Infections; HIV Seropositivity | Details |
| LF-0376 | LF-0376 | Phase 1 Clinical | Wuxi Hillhouse biomedicine Technology Co Ltd | Solid tumours; Liver Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Colorectal Neoplasms; Lymphoma | Details |
| OB-002 | OB-002; OB-002M; OB-002O; OB-002H; OB-002C; 5P12-RANTES; 5P12-RANTES-E66S | Phase 1 Clinical | Mintaka Medical Research Foundation | HIV Infections; Stomach Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.
A-Z
